Blue Light Cystoscopy |view more
Document
Implementing a New Standard of Care for Bladder Cancer*
Thomas Cangiano, MD, Board-certified Urologist at Advent Health Altamonte Springs, FL, describes his initial experiences and observations when using the BLCC approach on his patients.
Video
Mary Beth Ballard’s story with Blue Light Cystoscopy*
At 28 years old, Mary Beth Ballard received a bladder cancer diagnosis that would change her life. After getting the news and seeking multiple opinions, doctors at Vanderbilt University Medical Center were able to optimizing KARL STORZ ...
Document
KARL STORZ Blue Light Cystoscopy with Cysview® System Brochure*
KARL STORZ Blue Light Cystoscopy with Cysview® System Brochure
Video
UH 400 Surgical Generator: Smarter Energy Delivery
Video showing ARC technology and comparing true bipolar to monopolar and semi-bipolar.
Videos |view more
Video
Proper Care and Maintenance of Your Flexible Ureteroscope
Maximize your service life and protect your investment by following these basic tips concerning setup, cleaning, and transport.
Video
The Standard of Care for Bladder Cancer*
KARL STORZ Blue Light Cystoscopy with Cysview® The First and only FDA-approved technology for the enhanced detection of bladder cancer.
Video
Surgical Technique: Minimally Invasive Percutaneous Nephrolithotomy (MIP)
Overview of kidney stone removal
Video
Flex-XC: Setting New Standards in Stone Management
Reach Stones Others Can’t. The ONLY Digital Ureteroscope to Reach Stones in Acute Angled Calicies.
Video
Minimally Invasive PCNL: More Than a Mini-Perc
Send Your Patients Home Stone Free with Just a Band-aid.
Video
A Step-By-Step Guide to Renal Access for Percutaneous Nephrolithotomy
This instructional video has been prepared by Julio Davalos,MD, of Chesapeake Urology Associates, who is also affiliated with theUniversity of Maryland.
Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.
Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain.
Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed.
Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition.
Cysview is approved for use with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components.
Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.
Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLCTM) as an adjunct to the white light cystoscopy.
Here to Help
As you are preparing for increased patient volumes, we want to make sure you have access to the critical items needed to take care of your patients.
If you need flexibility, customized payment options are available to you. For a limited time we are offering deferred payments until 2021 through KARL STORZ Capital Finance Group.
The products described in the videos, images, and documents on this site have been approved authorized by the company for use in the United States only. The materials on this site are provided exclusively as an educational service for medical professionals and do not necessarily reflect the views of KARL STORZ Endoscopy-America, Inc. The decision to apply any of the information on this site is at the sole discretion and choice of qualified medical personnel, who are advised to verify the applicability and the suitability for any particular situation. KARL STORZ cannot be held is not responsible for the misuse of any information on this site.
